Association of FTO rs9939609, TCF7L2 rs7903146, FABP2 rs1799883 polymorphisms with morbid obesity in women

Aim. Study the association of FTO rs9939609, TCF7L2 rs7903146, rs1799883 FABP2 polymorphisms on the risk of morbid obesity in women. Materials and methods. The morbid obesity group (n=192, average age 57.02 ± 7.16 years, BMI > 40 kg/m2) and the control group (n=450, average age 55.44 ± 7.41 years, BMI 20-25 kg/m2) were formed from the DNA bank of the international HAPIEE research. Genotyping was performed by PCR-RFLP and real time PCR using TaqMan (Applied Biosystems, USA). The results were statistically processed in the SPSS software. Results. There were no statistically significant differences in the genotype frequencies of TCF7L2 rs7903146, FABP2 rs1799883 (р>0.05) between the morbid obesity group and the control group. The morbid obesity group has the number of TT genotype carriers of FTO rs9939609 polymorphism less (26,6%) and AT genotype more (53,6%) than in the control group (38,4%; 45,1%, respectively), (OR=0.58, 95%CI 0.4-0.84, p=0.004; OR=1.41, 95%CI 1.003-1.98, p=0.047, respectively). Conclusion. AT genotype of FTO rs9939609 is the genotype of the risk of morbid obesity in women and TT genotype has a protective effect against it. Polymorphisms TCF7L2 rs7903146, FABP2 rs1799883 were not associated with morbid obesity in the studied group of women.

morbid obesity, BMI, FTO, rs9939609, TCF7L2, rs7903146, FABP2, rs1799883

1. Статистическая информация [Электронный ресурс]. - https://www.rosminzdrav.ru/documents/6686-statisticheskaya-informatsiya

2. Ершова E.В., Трошина Е.А., Федорова О.С. и др. Морбидное ожирение - возможности консервативной терапии. Ожирение и метаболизм. 2010;7(4):40-43.

3. Yang W., Tanika K., He J. Genetic epidemiology of obesity. Epidem Rev. 2007(29):49-61. doi:10.1093/epirev/mxm004.

4. Salim S., Kartawidjajaputra F., Suwanto A. Association of FTO rs9939609 and CD36 rs1761667 with Visceral Obesity. J Nutr Sci Vitaminol (Tokyo). 2020;66:329-335. doi:10.3177/jnsv.66.S329.

5. Bride L., Naslavsky M., Lopes Yamamoto G. et al. TCF7L2 rs7903146 polymorphism association with diabetes and obesity in an elderly cohort from Brazil. PeerJ. 2021 May 9:e11349. doi:10.7717/peerj.11349.

6. Wang H., Dong S., Xu H. et al. Genetic variants in FTO associated with metabolic syndrome: a meta- and gene-based analysis. Mol Biol Rep. 2012 May;39(5):5691-8. doi:10.1007/s11033-011-1377-y.

7. Liu Y., Wu G., Han L. et al. Association of the FABP2 Ala54Thr polymorphism with type 2 diabetes, obesity, and metabolic syndrome: a population-based case-control study and a systematic meta-analysis. Genet Mol Res. 2015 Feb 6;14(1):1155-68. doi:10.4238/2015.

8. Амельянович М.Д., Морозик П.М., Гончар А.Л. и др. Генетические факторы риска развития метаболического синдрома. Молекулярная и прикладная генетика. 2013(16):24-31.

9. Гречухина Е.И., Гречухина М.И., Кывыржик Д.С. и др. Ген FTO как генетический фактор. Universum: медицина и фармакология. 2019;2(57):4-6.

10. Zhou Y., Hambly B.D., McLachlan C.S. FTO associations with obesity and telomere length. J Biomed Sci. 2017 Sep 24(1):65. doi:10.1186/s12929-017-0372-6.

11. Rivera M., Locke A.E., Corre T. et al.Interaction between the FTO gene, body mass index and depression: meta-analysis of 13701 individuals. Br J Psychiatry. 2017 Aug 211(2):70-76. doi:10.1192/bjp. bp.116.183475.

12. Garcés Da Silva M.F., Guarin Y.A., Carrero Y. et al. Postprandial Hypertriglyceridemia Is Associated with the Variant 54 Threonine FABP2 Gene. J Cardiovasc Dev Dis. 2018 Sep 13;5(3):47. doi:10.3390/jcdd5030047.

13. Мельникова Е.С., Рымар О.Д., Иванова А.А. и др. Ассоциация полиморфизмов генов TCF7L2, FABP2, KCNQ1, ADIPOQ с прогнозом развития сахарного диабета 2-го типа. Терапевтический архив. 2020;92(10):40-47.

14. Aboelkhair N.T., El-Edel R.H., Kasem H.E. et al. TCF7L2 gene polymorphism as a risk for type 2 diabetes mellitus and diabetic microvascular complications. Mol Biol Rep. 2021 Jun 48(6):5283-5290. doi:10.1007/s11033-021-06537-0.